Literature DB >> 2260992

Effects of granulocyte-macrophage colony-stimulating factor on 3'-azido-3'-deoxythymidine uptake, phosphorylation and nucleotide retention in human U-937 cells.

R K Dhawan1, S Kharbanda, M Nakamura, T Ohno, D Kufe.   

Abstract

Previous studies have demonstrated that granulocyte-macrophage colony-stimulating factor (GM-CSF) both increases and decreases levels of 3'-azido-3'-deoxythymidine (AZT) nucleotides in certain human myeloid cells. The present studies have examined the effects of GM-CSF on AZT metabolism in U-937 cells. The results demonstrate that GM-CSF stimulated AZT nucleotide formation in these cells. This stimulation was detectable during concurrent exposure to GM-CSF and AZT or as a result of pretreatment with GM-CSF. The GM-CSF-induced enhancement in AZT nucleotide formation was associated with a 4-fold increase in AZT uptake. The finding that uptake of AZT into U-937 cells was only partially sensitive to 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine (NBMPR) suggested a process primarily involving nonfacilitated diffusion. The results also demonstrate that treatment of U-937 cells with GM-CSF was associated with nearly a 2-fold increase in thymidine kinase activity. Moreover, the findings indicate that retention of AZT-MP and AZP-TP was prolonged significantly (P less than 0.05 and P less than 0.01 respectively) in association with GM-CSF treatment. Taken together, these results suggest that GM-CSF enhances the formation of AZT nucleotides by increasing AZT uptake and phosphorylation, as well as increasing retention of phosphorylated derivatives.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2260992     DOI: 10.1016/0006-2952(90)90589-d

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Tissue disposition of zidovudine and its phosphorylated metabolites in zidovudine-treated healthy and retrovirus infected mice.

Authors:  H H Chow; G Brookshier; P Li
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

2.  S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

Authors:  T Fujiwara; A Sato; M el-Farrash; S Miki; K Abe; Y Isaka; M Kodama; Y Wu; L B Chen; H Harada; H Sugimoto; M Hatanaka; Y Hinuma
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 3.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 4.  Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.

Authors:  Maria Petrina; Jacqueline Martin; Sameh Basta
Journal:  Cytokine Growth Factor Rev       Date:  2021-01-09       Impact factor: 7.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.